BETonMACE shows apabetalone treatment was associated with 41% reduction in hospitalizations for heart failure in patients with type 2 diabetes and recent Acute Coronary Syndrome
Preclinical findings support a favourable role of apabetalone in CVD patients with type 2 diabetes by correcting epigenetic dysregulation of the innate immune responseCALGARY, Alberta, March 31, 2020 (GLOBE NEWSWIRE) — Resverlogix Corp. (“Resverlogix” or the “Company”) (TSX:RVX) announced today its participation at the American College of Cardiology Scientific Sessions, together with the World Congress of Cardiology (ACC.20/WCC), presenting two virtual posters made available on demand via an eAbstracts System starting Saturday, March 28, 2020. These posters are available on the ACC.20/WCC website (additional details on a Moderated Poster below) and the Company’s website HERE.Poster #1: The BET Protein Inhibitor Apabetalone Reduces Congestive Heart Failure Incidence in Patients with Acute Coronary Syndrome and Diabetes: Results from the BETonMACE TrialPoster HighlightsApabetalone treatment was associated with fewer hospitalizations for heart failure – hazard reduction of 41% – in patients with type 2 diabetes and recent Acute Coronary Syndrome (ACS)When combined with cardiovascular death, similar trends were observed – hazard reduction 28%Future studies are warranted to define the potential for BET inhibition with apabetalone in the prevention and treatment of heart failure in patients with diabetes and ACSModerated Poster #2: Epigenetic Reader Inhibitor Apabetalone (RVX-208) Counters Proinflammatory Hyperactivation of CD14+ Monocytes from Patients with Type 2 Diabetes and Cardiovascular DiseasePoster Highlights – visit HERE to access the audio presentation associated with this posterMonocytes from diabetic patients with cardiovascular disease (CVD) show a hyperactive pro-inflammatory phenotype ex vivo, despite standard of care therapyApabetalone reverses this hyperactivation by downregulating key inflammatory genes and secreted cytokinesGene expression in monocytes from diabetic CVD patients shows a greater sensitivity to BET inhibition as compared to monocytes from control subjects. Data suggests a greater transcriptional dependency on BET proteins in diseased conditionsFindings support the development of apabetalone as a therapy for high risk CVD patients with epigenetic dysregulation of the innate immune response, which could be a common feature in post-ACS type 2 diabetes patientsAbout ResverlogixResverlogix is developing apabetalone (RVX-208), a first-in-class, small molecule that is a selective BET (bromodomain and extra-terminal) inhibitor. Apabetalone is the first therapy of its kind to have been granted US FDA Breakthrough Therapy Designation – for a major cardiovascular indication – to help facilitate a time-efficient drug development program including planned clinical trials and plans for expediting the manufacturing development strategy.BET inhibition is an epigenetic mechanism that can regulate disease-causing genes. Apabetalone is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. This selective inhibition of apabetalone on BD2 produces a specific set of biological effects with potentially important benefits for patients with high-risk cardiovascular disease, diabetes mellitus, chronic kidney disease, end-stage renal disease treated with hemodialysis, neurodegenerative disease, Fabry disease, peripheral artery disease and other orphan diseases, while maintaining a well described safety profile.Resverlogix common shares trade on the Toronto Stock Exchange (TSX:RVX).Follow us on:Twitter: @Resverlogix_RVXLinkedIn: https://www.linkedin.com/company/resverlogix-corp-/For further information please contact:Investor Relations
Email: [email protected]
Phone: 403-254-9252
Or visit our website: www.resverlogix.comThis news release may contain certain forward-looking information as defined under applicable Canadian securities legislation, that are not based on historical fact, including without limitation statements containing the words “believes”, “anticipates”, “plans”, “intends”, “will”, “should”, “expects”, “continue”, “estimate”, “forecasts” and other similar expressions. In particular, this news release includes forward looking information related to data from Phase 3 Clinical Trial BETonMACE, further supporting the potential commercialization of apabetalone and the potential role of apabetalone in the treatment of patients with cognitive disorders, high-risk cardiovascular disease, diabetes mellitus, chronic kidney disease, end-stage renal disease treated with hemodialysis, Fabry disease, peripheral artery disease and other orphan diseases. Our actual results, events or developments could be materially different from those expressed or implied by these forward-looking statements. We can give no assurance that any of the events or expectations will occur or be realized. By their nature, forward-looking statements are subject to numerous assumptions and risk factors including those discussed in our Annual Information Form and most recent MD&A which are incorporated herein by reference and are available through SEDAR at www.sedar.com. The forward-looking statements contained in this news release are expressly qualified by this cautionary statement and are made as of the date hereof. The Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Bay Street News
